Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)

Cardiovascular Disorder Clinical Trial

Official title:

A Multicenter, Open Study To Evaluate The Efficacy Of Ezetimibe 10 Mg Added On Statin Therapy, In Reducing LDL Cholesterol To Target Levels In Patients After Acute Coronary Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00652717
• Other study ID #: 0653A-150
• Secondary ID: 2008_009
• Status: Completed
• Phase: Phase 4
• Start date: February 1, 2005
• Est. completion date: August 4, 2005

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Collecting local data, safety and experience trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 280
• Est. completion date: August 4, 2005
• Est. primary completion date: February 15, 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients; Post Acute Coronary Syndrome

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Cardiovascular Disorder

Intervention

Drug:
• Ezetimibe
Ezetimibe 10 mg daily for 42 days.
• simvastatin
simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Organon and Co

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LDL levels		42 Days
Secondary	Safety measures		42 days
Secondary	Total cholesterol levels.		42 Days